Boston Gene Tumor Portrait Test – pro
he Tumor Portrait test identifies key biomarkers for response to various therapies in patients with advanced solid tumors, offering the first comprehensive genomic profiling combined with tumor microenvironment (TME) analysis. The test provides personalized treatment options by integrating the results of three NGS assays in a single, streamlined report:
The test is fairly new and not prospectively studied; however, more importantly, there is no immediate benefit tot testing. There is no information on how to select adjuvant therapy based on this test results. If and when metastatic progression occurrs, this or other tests may be useful and can be performed at that time.
Sternberg CN, Shin N, Chernyshov K, Calabro F, Cerbone L, Procopio G, Miheecheva N, Sagaradze G, Zaichikova A, Samarina N, Boyko A, Brown JH, Yunusova L, Guevara D, Manohar J, Sigouros M, Al Assaad M, Elemento O, Mosquera JM. Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment. Front Oncol. 2022 Oct 31;12:1006017. doi: 10.3389/fonc.2022.1006017. PMID: 36387205; PMCID: PMC9661726.
Gregory G Cote et al, Abstract 244: Use of comprehensive molecular profiling to identify additional clinically-relevant alterations compared to targeted gene panels. Cancer Research Volume 83, Issue 7_Supplement 1 April 2023
Al Assaad M, Shin N, Sigouros M, Manohar J, Antysheva Z, Kotlov N, Kiriy D, Nikitina A, Kleimenov M, Tsareva A, Makarova A, Fomchenkova V, Dubinina J, Boyko A, Almog N, Wilkes D, Escalon JG, Saxena A, Elemento O, Sternberg CN, Nanus DM, Mosquera JM. Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis. Front Oncol. 2024 Jan 22;13:1274163. doi: 10.3389/fonc.2023.1274163. PMID: 38318324; PMCID: PMC10838960.